Drugs in Dev. Genetic Disease
Phase I
Denmark 
Lead Product(s) : NMD670
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NMD Pharma Receives IND Clearance from FDA to Start Phase 2 Trial of NMD670 for CMT
Details : NMD670 is a first-in-class small molecule inhibitor of ClC-1. It is being developed by NMD Pharma for the treatment of patients with charcot-marie-tooth disease.
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : NMD670
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona Completes Submission of Manufacturing Data for Tesomet Capsules To U.S. FDA
Details : Tesomet capsules contain two active ingredients as microspheres of fixed-dose combination therapy of tesofensine (triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker) used for treatment for hypothalamic obesity and Prader-Will...
Product Name : Tesomet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome
Details : Saniona is preparing to start a Phase 2b study of Tesomet in Prader-Willi Syndrome this year. In a Phase 2a trial, adults patients receiving Tesomet achieved a significant reduction in hyperphagia and a clinically meaningful reduction in body weight at a...
Product Name : Tesomet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
